Key result
Compound A and sildenafil reduce ventricular hypertrophy and UACR in diabetic hypertensive mice.
Why the study?
Although hypertension and diabetic nephropathy frequently complicate ESRD, relevant animal models remain unavailable, prompting testing of PDE4 and PDE5 inhibitors in a new model.
Do PDE4 and PDE5 inhibitors exhibit nephroprotective and cardioprotective effects in DOCA-salt hypertensive UNx KKAy mice?
Do PDE4 and PDE5 inhibitors exhibit nephroprotective and cardioprotective effects in DOCA-salt hypertensive UNx KKAy mice?
PDE4 and PDE5 inhibitors demonstrate nephroprotective and cardioprotective effects in a novel mouse model of diabetic nephropathy with hypertension.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PDE4/PDE5 inhibition in hypertensive diabetic nephropathy; leaves open translation to human cardiorenal disease.
Diabetic nephropathy (DN) is a leading cause of end‐stage renal disease (ESRD). Hypertension increases kidney stress, which deteriorates function, and leads to peripheral renal vascular resistance. Long‐term hypoperfusion promotes interstitial fibrosis and glomerular sclerosis, resulting in nephrosclerosis. Although hypertension and DN are frequent ESRD complications, relevant animal models remain unavailable. We generated a deoxycorticosterone acetate (DOCA)‐salt hypertensive uni‐nephrectomized (UNx) KKA y mouse model demonstrating hypertension, hyperglycemia, cardiac hypertrophy, kidney failure, increased urinary albumin creatinine ratio (UACR), and increased renal PDE4D and cardiac PDE5A mRNA levels. We hypothesized that the novel PDE4 selective inhibitor, compound A, and PDE5 inhibitor, sildenafil, exhibit nephroprotective, and cardioprotective effects in this new model. Compound A, sildenafil, and the angiotensin II receptor blocker, irbesartan, significantly reduced ventricular hypertrophy and pleural effusion volume. Meanwhile, compound A and sildenafil significantly suppressed the UACR, urinary kidney injury molecule‐1, and monocyte chemoattractant protein‐1 levels, as well as that of renal pro‐fibrotic marker mRNAs, including collagen 1A1, fibronectin, and transforming growth factor‐beta (TGF‐β). Moreover, compound A significantly suppressed TGF‐β‐induced pro‐fibrotic mRNA expression in vitro in all major kidney lesions, including within the glomerular mesangial region, podocytes, and epithelial region. Hence, PDE4 and PDE5 inhibitors may be promising treatments, in combination with irbesartan, for DN with hypertension as they demonstrate complementary mechanisms.
No takes yet. Share an insight, caveat, or question.
Nio et al. (2020) studied Diabetic nephropathy with hypertension. Compound A (PDE4 inhibitor) and sildenafil (PDE5 inhibitor) was evaluated on ventricular hypertrophy, pleural effusion volume, UACR, and pro-fibrotic markers.
Synapse has enriched 10 related papers. Consider them for comparative context: